Earnings call transcript: Microba Life Sciences posts strong FY26 growth in Q4 2026

Microba Life Sciences reported FY26 core diagnostic testing momentum: core testing volume up 78% Y/Y and core testing revenue up 92% Y/Y, alongside strong region-specific growth (Australia Q4 tests up 54% to 5,311; U.K. Q4 tests up 92% to 825). Management reiterated its path to full-group cash flow breakeven on a run-rate basis in calendar 2027 and is on track to launch GI Navigator in September 2026, with early-access already generating 35 sales. However, profitability remains future-led (LTM EBITDA -$15.39M) and the company recently raised AUD 5M via placement plus an AUD 1M SPP, while the stock was little changed, trading near $0.04 (down 2.44% on the day).

Analysis

The real signal is that leading-edge AI demand is still absorbing capacity faster than the market can fully discount, which supports TSM’s pricing power and keeps the semiconductor stack in a favorable operating regime. The second-order winners are the bottlenecked ecosystem names with tight exposure to advanced nodes and packaging; the losers are laggards that depend on broad-based handset/PC recovery rather than AI mix. Near term, this is more multiple-supportive than earnings-upgrade-driven, so the move can persist for weeks even if the next print is merely “good” rather than explosive.

Microba reads differently: the operating trajectory is improving, but this is still a financing story wearing a growth hat. In small-cap diagnostics, adoption growth only matters if it converts into visible runway extension and lower cash burn; otherwise the equity tends to reprice around dilution risk, not unit growth. The competitive risk is that incumbents can replicate a validated workflow faster than the market expects, so the moat has to come from clinician habit, reimbursement, and distribution depth—not just product novelty.

Contrarian view: consensus is likely underweighting how concentrated AI capex is in a handful of names, which makes TSM a cleaner way to express the theme than crowded U.S. AI beneficiaries. On Microba, the market may be overestimating partnership optionality and underestimating the time it takes for a niche diagnostic to become cash generative. For TSM, the key falsifier is any downtick in hyperscaler capex commentary over the next 1-3 months; for Microba, it is failure to show a clear burn-rate inflection by the next funding window.

Key Decisions for Investors

• Buy TSM on the first 1-2% pullback after the print; use a 1-3 month hold and look for follow-through from NVDA/MSFT/AMZN capex commentary. Risk/reward is favorable as long as AI spend remains concentrated.
• Pair long TSM / short GFS as a relative-value expression of the leading-edge foundry winner versus a more cycle-sensitive competitor. Exit if TSM guidance weakens or GFS narrows the process gap materially.
• Do not chase Microba here; treat it as a watchlist name until management shows a measurable cash-burn inflection and no further dilution over the next 2-4 quarters.
• If seeking optionality on AI supply-chain persistence, favor TSM call spreads over outright equity only if implied vol stays below recent realized vol; otherwise stay with stock for cleaner exposure.